How New Policies are Impacting Market Sustainability

EP: 1.Industry Voices on Current Pricing and Reimbursement Models

EP: 2.Navigating Regulatory Barriers within Market Access

EP: 3.Effective Real-World Evidence for Adding Value to a Clinical Trial

EP: 4.Harmonizing the Payer Perspective with Real-World Evidence

EP: 5.Challenges for Bringing Orphan Drugs to Market

EP: 6.Strategies in Today’s Market for Pricing and Reimbursement Models

EP: 7.The Ins and Outs of Value-Based Contracts: Timing, Evidence, and Risk Alignment

Now Viewing

EP: 8.How New Policies are Impacting Market Sustainability

EP: 9.Rethinking Market Strategy within a Patient-Centric Era

The Most Favored Nation (MFN) pricing policy aims to align US drug prices with lower international rates. The panelists share varying perspectives on this policy, including its uncertain future, the need for greater pricing transparency, and how manufacturers might defend price differences based on value, clinical investment, and regulatory requirements. Also discussed are potential overlaps with the Inflation Reduction Act and the crucial role that proactive advocacy plays in a changing policy landscape.

Key discussion topics include:

• The potential impact of MFN pricing on US drug costs and the current market.
• Why pricing transparency and value justification are increasingly essential for pharmaceutical companies.
• The role of scenario planning and value proposition refinement in navigating regulatory uncertainty.